Immunosuppression with cyclophosphamide favors reinfection with recombinant Toxoplasma gondii strains

L.A. Silva; G.P. Brandão; B.V. Pinheiro; R.W.A. Vitor

doi:10.1051/parasite/2012193249

All issues

Volume 19 / No 3 (August 2012)

Parasite, 19 3 (2012) 249-257

Full HTML

Open Access

Original contribution

Table II.

Survival, brain cysts and PCR of BALB/c mice primary infected with the D8 or ME49 strains, immunosuppressed or non-immunosuppressed with cyclophosphamide (Cy), and challenged 45 days after primary infection with the CH3 or EGS strains of Toxoplasma gondii.

			Reinfection		PCR-RFLP^e n/N (%)
	Group^a	Strains/Immunosuppression^b	Survival^c n/N (%)	Cyst number^d	cS10-A6 locus	L363 locus
BALB/c mice primary infected with D8 strain of T. gondii	1	D8+CH3	10/10 (100)	230,0 ± 127,4	0/10 (0)	ND
	2	D8+CH3/Cy	10/10 (100)	365,0 ± 219,9	0/10 (0)	ND
	3	D8+EGS	10/10 (100)	135,0 ± 66,9^f	9/10 (90)	ND
	4	D8+EGS/Cy	4/10 (40)	662,5 ± 579,3^f	2/4 (50)	ND
	5	D8	10/10 (100)	185,0 ± 91,4	ND	ND
	6	D8/Cy	10/10 (100)	140,0 ± 69,9	ND	ND
	7	CH3	0/10 (0)	NS	ND	ND
	8	EGS	0/10 (0)	NS	ND	ND
	9	Naive/Cy	10/10 (100)	0	ND	ND

BALB/c mice primary infected with ME49 strain of T. gondii	10	ME49+CH3	9/9 (100)	551,1 ± 270,9	ND	4/9 (44,4)
	11	ME49+CH3/Cy	7/9 (77,8)	350,0 ± 155,5	ND	5/7 (71,4)
	12	ME49+EGS	8/9 (88,9)	2543,7 ± 3646,9^g	ND	8/8 (100)
	13	ME49+EGS/Cy	0/9 (0)	NS	ND	NS
	14	ME49	8/8 (100)	312,5 ± 138,2^g	ND	ND
	15	ME49/Cy	7/8 (87,5)	250,0 ± 141,4	ND	ND
	16	CH3	0/9 (0)	NS	ND	ND
	17	EGS	0/9 (0)	NS	ND	ND
	18	Naive/Cy	9/9 (100)	0	ND	ND

^a

Experimental groups 1–18 are described on details in “Material and Methods”. The experiments were repeated twice and provided similar results.

^b

It indicates: strain of primary infection + strain of challenge (when performed) / Cy treatment (when performed). Naive: mice without infection.

^c

Number of survivors (n) out of the total number of mice challenged (N).

^d

Mean number of brain cysts (and standard deviation) evaluated 30 days post challenge.

^e

Number of mice presenting the two strains (n) (positive PCR at cS10-A6 or L363 locus) out of the total number of survivors after challenge (N).

^f

Significant difference between mice primary infected with the D8 strain and challenged with the EGS strain and mice primary infected with the D8 strain, Cy-immunosuppressed and challenged with the EGS strain, p < 0.05.

^g

Significant difference between mice primary infected with the ME49 strain and challenged with the EGS strain and mice primary infected with the ME49 strain, p < 0.05. NS: No survival; ND: Not done.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.